Microdose Announces MindBio Therapeutics as Wonderland 2022 Platinum Sponsor

The article Microdose Announces MindBio Therapeutics as Wonderland 2022 Platinum Sponsor was originally published on Microdose.

The leader in the business of psychedelics, Microdose is taking the next step in top-notch industry events with Wonderland 2022. Pulling off such a massive undertaking wouldn’t be possible without the support of our sponsors, they are crucial to both the Wonderland event and the future of the psychedelic medicine industry.

So it’s an honor for Microdose to announce MindBio Therapeutics as a Platinum Sponsor for Wonderland: Miami 2022.

MindBio’s Justin Hanka will be at Wonderland for the following events:

• Press Lunch on November 3rd, 12:00 pm EST
• Microdosing with LSD panel on November 4th 2:10 pm EST
• The Current State Of Clinical Trial Development panel on November 5th 9:00 am EST

MindBio Therapeutics is a clinical-stage drug development company pioneering microdosing research and advancing emerging therapies to treat a range of debilitating health conditions such as depression, anxiety, chronic pain, cognitive impairment, and PTSD.

Their flagship program is a Phase 1 clinical trial for Microdosing LSD. MindBio’s scientific team is completing a world-first clinical trial of its kind, administering LSD microdoses in 80 healthy patients, with treatments taken at home.

This May, MindBio completed its Phase 1 clinical trial, the largest safety study of its kind, a randomized, double-blind placebo-controlled study. The results of which will support the development of MindBio’s intellectual property and progression toward commercialization of treatments for mental health conditions. MindBio is looking forward to analyzing the data from the Phase 1 clinical trial to further inform its planned Phase 2 clinical trials.

MindBio and its research collaborators at the University of Auckland in New Zealand have also received a grant of NZ$1.44 million from the Health Research Council of New Zealand to conduct a trial of LSD (Lysergic Acid Diethylamide) microdosing in patients with Major Depressive Disorder.

The company is also developing a Phase 2 clinical trial in late-stage cancer patients. This study will evaluate the feasibility of conducting a randomized controlled trial examining psychedelic-microdose assisted therapy alongside doses of either psilocybin or LSD, microdose or placebo.

See below for MindBio co-founder Justin Hanka kicking off Microdose’s virtual LSD Conference:

therapeutics
psychedelics
psilocybin
lsd
lysergic acid
psychedelic
microdosing
therapy
major depressive disorder
depressive disorder
depression
anxiety
ptsd